WINNIPEG, MB / ACCESSWIRE / June 24, 2024 / Medicure Inc. ('Medicure' or the 'Company') (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today announces it has signed an asset purchase agreement ('Agreement') with CanAm Bioresearch Inc.

温尼伯，MB/ACCESSWIRE/June 24，2024/Medicure Inc.（“Medicure”或“公司”）（TSXV:MPH）（OTC PINK:MCUJF），一家专注于为美国市场的患者和处方者开发和商业化药品和保健产品的公司，今天宣布与CanAm Bioresearch Inc.签署了资产购买协议（“协议”）。

('CanAm') for the acquisition of the patent and intellectual property related to the discovery of new chemical entities that can be developed for therapeutic use (the 'Proposed Transaction')..

（“CanAm”）获得与发现可用于治疗用途的新化学实体有关的专利和知识产权（“拟议交易”）。

Medicure believes that the new chemical entities hold promise to provide improvements over existing lead compounds in alignment with the treatment of diseases being targeted by Medicure, and could provide significant value upon completion of all required non-clinical and clinical studies and regulatory approval.

Medicure认为，新的化学实体有望改进现有的先导化合物，以适应Medicure针对的疾病的治疗，并且在完成所有必需的非临床和临床研究以及监管批准后，可以提供重大价值。

These new chemical entities are not being applied in Medicure's current Phase 3 study evaluating the use of MC-1 for the prevention or treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency..

这些新的化学实体没有应用于Medicure目前的第三阶段研究，该研究评估了MC-1用于预防或治疗与吡ido（am）ine 5'-磷酸氧化酶（PNPO）缺乏症相关的癫痫发作。

Pursuant to the Agreement, Medicure International Inc., a wholly owned subsidiary of Medicure, has agreed to acquire, subject to the conditions contained in the Agreement, all of the assets of CanAm as they relate to the business of developing pyridoxal 5'-phosphate analogues ('P5P Analogues'), the processes for their preparation, compositions containing P5P Analogues, and methods of medical treatment containing P5P Analogues (the 'Assets').

根据该协议，Medicure的全资子公司Medicure International Inc.同意根据协议中包含的条件收购CanAm的所有资产，因为这些资产与开发吡ido醛5’-磷酸类似物（“P5P类似物”）的业务、其制备过程、含P5P类似物的组合物以及含P5P类似物的医疗方法（“资产”）有关。

In consideration for the Assets, Medicure has agreed to pay to CanAm a $100,000 cash payment on the closing date, in addition to the following milestone payments: (i) $500,000, earned upon Medicure filing its first investigational new drug application ('IND Application') related to P5P Analogues; (ii) $250,000, earned upon the Medicure filing its first New Drug Application ('NDA') related to P5P Analogues; and (iii) $500,000, earned upon Medicure obtaining an NDA approval for P5P Analogues..

作为资产的对价，Medicure同意在截止日期向CanAm支付10万美元的现金付款，此外还有以下里程碑付款：（i）Medicure提交其第一份与P5P类似物相关的研究性新药申请（“IND申请”）时赚取的50万美元；（ii）在Medicure提交其与P5P类似物相关的第一份新药申请（“NDA”）时获得250000美元；（iii）Medicure获得P5P类似物的NDA批准后获得500000美元。

In addition, Medicure shall pay to CanAm 10% of net proceeds received with respect to transactions relating to the Assets, including: (i) the sale or transfer of all or substantially all of the Assets to a third party purchaser who is not an affiliate of Medicure; (ii) any license to develop, commercialize, use, offer for sale, sell, import, export or exploit P5P Analogues up to a maximum value payable to CanAm of $20,000,000; and (iii) the sale of an United State Food and Drug Administration priority review voucher obtained in connection with the development of P5P Analogues..

此外，Medicure应向CanAm支付与资产相关交易收到的净收益的10%，包括：（i）将所有或实质上所有资产出售或转让给非Medicure关联公司的第三方购买者；（ii）开发、商业化、使用、要约销售、销售、进口、出口或开发P5P类似物的任何许可证，最高金额为20000000美元；（iii）出售与P5P类似物开发相关的美国食品和药物管理局优先审查凭证。

In the event Medicure retains a contract research organization ('CRO') to provide services related to development of P5P Analogues, CanAm, a CRO, would be entitled to tender a bid for such services, in addition to having an opportunity to match quotes for CRO services provided by third-party organizations..

如果Medicure聘请合同研究组织（“CRO”）提供与P5P类似物开发相关的服务，则CRO CanAm将有权对此类服务进行投标，此外还有机会对第三方组织提供的CRO服务进行报价。

In the event that Medicure does not file an IND Application within 7 years from the closing date of the Proposed Transaction, CanAm shall have the option at any time after such date to repurchase the Assets from Medicure, at a price equal to the aggregate of all expenses incurred by Medicure in connection with the development of P5P Analogues, but, in any event, not exceeding the sum of $6,500,000 USD..

如果Medicure在拟议交易结束之日起7年内未提交IND申请，CanAm有权在该日期后的任何时间从Medicure回购资产，价格等于Medicure开发P5P类似物所产生的所有费用的总和，但无论如何不得超过6500000美元。

Closing of the Proposed Transaction is subject to a number of terms and conditions, including without limitation, CanAm completing certain intellectual property filings with respect to the patent application it holds for P5P Analogues, the parties obtaining all necessary consents, orders and regulatory approvals, including approval of the TSX Venture Exchange ('TSXV'), and certain other customary closing conditions..

拟议交易的完成受若干条款和条件的约束，包括但不限于加拿大完成其持有的P5P类似物专利申请的某些知识产权备案，各方获得所有必要的同意、订单和监管批准，包括TSX风险交易所（“TSXV”）的批准，以及某些其他惯常的完成条件。

All dollars are Canadian dollars unless otherwise noted.

除非另有说明，所有美元均为加元。

Founded in 2000, CanAm is a privately held medicinal chemistry contract research organization providing drug discovery services, and is located in Winnipeg, Canada.

CanAm成立于2000年，是一家提供药物发现服务的私营药物化学合同研究组织，位于加拿大温尼伯。

As Medicure's CEO and Chairman of the board of directors, Dr. Albert D. Friesen, is the President and shareholder of the parent company of CanAm, the Proposed Transaction will constitute a 'related party transaction' in accordance with Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ('MI 61-101').

由于Medicure首席执行官兼董事会主席Albert D.Friesen博士是CanAm母公司的总裁和股东，因此根据多边文书61-101“特殊交易中少数股东证券持有人的保护”（“MI 61-101”），拟议交易将构成“关联方交易”。

The Proposed Transaction will be exempt from the formal valuation and the minority shareholder approval requirements of MI 61-101, as no securities of Medicure are listed or quoted on any of the specified markets listed in section 5.5(b) of MI 61-101 and, at the time the Proposed Transaction was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Proposed Transaction, insofar as it involves interested parties, exceeded 25% of Medicure's market capitalization..

拟议交易将不受MI 61-101的正式估值和少数股东批准要求的约束，因为在MI 61-101第5.5（b）节所列的任何特定市场上都没有Medicure证券上市或报价，并且在拟议交易达成协议时，拟议交易标的的公平市价和对价的公平市价（只要涉及利益相关方）均未超过Medicure市值的25%。

Due to Dr. Friesen's involvement with CanAm, a special committee (the 'Special Committee') of independent directors was established to consider the Proposed Transaction without conflict of interest and to negotiate the terms of the Agreement. The Special Committee unanimously determined that the Proposed Transaction is in the best interests of Medicure and recommended that the board of directors of Medicure approve the Agreement..

由于Friesen博士参与了CanAm，成立了一个独立董事特别委员会（“特别委员会”），以审议拟议交易，不产生利益冲突，并谈判协议条款。特别委员会一致认为，拟议交易符合Medicure的最大利益，并建议Medicure董事会批准该协议。。

Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S.

Medicure是一家专注于为美国市场的患者和处方者开发和商业化药品和保健产品的公司。

subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug Inc. ('Marley Drug®'), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving access to medications for all Americans together with exceptional customer service and free home delivery.

子公司Medicure Pharma Inc.Medicure还经营Marley Drug Inc.（“Marley Drug®”），这是一家为所有50个州、华盛顿特区和波多黎各提供服务的药房子公司。Marley Drug®致力于改善所有美国人获得药物的机会，同时提供卓越的客户服务和免费送货上门服务。

For more information visit www.marleydrug.com. For more information about Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastat.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information..

。有关ZYPITAMAG®的更多信息，请访问www.ZYPITAMAG.com或参阅完整的处方信息。

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

TSXV及其监管服务提供商（定义见TSXV政策）均不对本版本的充分性或准确性负责。

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words 'believes', 'may', 'plans', 'will', 'estimates', 'continues', 'anticipates', 'intends', 'expects' and similar expressions, may constitute 'forward-looking information' within the meaning of applicable Canadian and U.S.

前瞻性信息：本新闻稿中包含的非历史事实声明，包括但不限于包含“相信”、“可能”、“计划”、“将”、“估计”、“继续”、“预期”、“打算”、“预期”和类似表述的声明，可能构成适用加拿大和美国含义内的“前瞻性信息”。

federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as 'forward-looking statements'). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances.

联邦证券法（此类前瞻性信息和前瞻性声明以下统称为“前瞻性声明”）。前瞻性陈述，包括根据公司的经验和对趋势、现状和预期发展的看法，以及公司认为在这种情况下相关和合理的其他因素，对公司管理层做出的估计、分析和意见。

More particularly and without limitation, this press release contains forward-looking statements and information regarding the completion of the Proposed Transaction, the acquisition of the Assets by Medicure and the ability of the new chemical compounds acquired to provide improvements over existing lead compounds.

更具体且不限于此，本新闻稿包含有关完成拟议交易、Medicure收购资产以及收购的新化合物改善现有先导化合物的能力的前瞻性声明和信息。

Except as may be required by Canadian securities laws, the Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place .

除加拿大证券法可能要求外，公司不承担任何义务更新或修订任何前瞻性声明，无论是由于新信息、未来事件或其他原因。前瞻性陈述中固有的已知和未知风险、不确定性和其他因素超出了公司的预测或控制能力，可能导致实际结果、事件或发展与此类前瞻性陈述中明示或暗示的任何未来结果、事件或发展产生重大差异，因此，提醒读者不要放置。

AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.

AGGRASTAT®（盐酸替罗非班）注射液，ZYPITAMAG®（匹伐他汀）片剂和Marley Drug®是注册商标。